Clearside Biomed Stock Price, News & Analysis

Clearside Biomedical (NASDAQ: CLSD) announced the issuance of three additional patents in the U.S. and Europe, bolstering its intellectual property portfolio, particularly for the SCS Microinjector. The U.S. Patent No. 10,722,396, expiring in 2034, covers the administration of axitinib. European patents include one for a device for therapeutic administration, expiring in 2031, and another for XIPERE™ treatment, expiring in 2033. With 21 U.S. and 20 European patents, Clearside aims to advance its pipeline, including three product candidates anticipated in clinical trials by year-end.

Clearside Biomedical (NASDAQ:CLSD) reports key updates and financial results for Q2 2020. The FDA accepted its IND application for CLS-AX (axitinib injectable suspension), marking a significant step in its suprachoroidal pipeline expansion. Clearside initiated two new preclinical programs and partnered with a new manufacturer for XIPERE, enhancing production efficiency. Despite a net loss of $5.8 million for Q2, up from $5.7 million, the company believes it has adequate cash resources to sustain operations until mid-2021, supported by its licensing revenue growth to $0.4 million.

Clearside Biomedical (Nasdaq: CLSD) announced that the FDA has accepted its IND application for CLS-AX, allowing the initiation of a Phase 1/2a clinical trial for wet AMD patients by year-end 2020. CLS-AX is a proprietary axitinib injectable suspension aimed at providing a long-acting treatment option. The trial will evaluate the safety and tolerability of CLS-AX via suprachoroidal injection after prior anti-VEGF treatments. This milestone reflects Clearside's progress in addressing significant needs within the ophthalmology market.

Clearside Biomedical (NASDAQ: CLSD) will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 9:10 a.m. ET. George Lasezkay, Pharm.D., J.D., CEO, and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer, will lead the presentation. A live and archived webcast will be accessible on the Clearside website for three months. Clearside is focused on innovative treatments for serious back of the eye diseases, utilizing its proprietary SCS Microinjector™ for targeted medication delivery.

Clearside Biomedical (CLSD) will report its Q2 2020 financial results on August 10, 2020, after market close. A conference call with management is set for 4:30 PM ET to discuss the results and provide updates. The company focuses on treatments targeting serious eye diseases using its proprietary SCS Microinjector®, facilitating targeted delivery of medications. This innovative technology aims to restore and preserve vision, directly addressing sight-threatening conditions.

Clearside Biomedical (Nasdaq: CLSD) announced presentations of its pipeline and SCS Microinjector at ASRS 2020 Virtual Annual Meeting. Notable findings included CLS-AX's tolerance and high potency for treating neovascular age-related macular degeneration (nAMD), suggesting potential for bi-annual therapy. Other studies highlighted the efficacy and safety of suprachoroidal delivery methods, particularly for non-infectious uveitis and macular edema. Overall, Clearside's developments continue to gain recognition in retinal disease treatments, with ongoing research warranted for various therapeutic applications.

Clearside Biomedical (Nasdaq:CLSD) announced promising results from preclinical studies on its CLS-AX treatment for neovascular age-related macular degeneration (nAMD), presented at the virtual ARVO 2020 Meeting. Data indicate CLS-AX provided sustained, targeted delivery and well-tolerated efficacy against neovascularization. Additionally, studies on complement inhibitors delivered via the SCS Microinjector show potential for long-acting treatments. The company’s partnership with Aura Biosciences for ocular cancer therapies further underlines the versatility of its delivery systems.

Clearside Biomedical reported significant growth in license revenue, reaching $4.1 million in Q1 2020, compared to $45,000 in Q1 2019, driven by a $4.0 million upfront payment from Arctic Vision. R&D expenses decreased to $3.8 million from $11.0 million in the same quarter last year, while net loss improved to $2.9 million or $0.07 per share, down from $15.4 million or $0.45 per share in Q1 2019. The NDA for XIPERE resubmission is targeted for Q4 2020. Cash reserves at March 31, 2020, stood at $20.9 million.